Use of Lacosamide in Children With Refractory Epilepsy.
Use of lacosamide in children with refractory epilepsy.
Filed under: Drug and Alcohol Rehabilitation
J Pediatr Pharmacol Ther. 2012 Jul; 17(3): 211-9
Buck ML, Goodkin HP
Lacosamide was approved by the US Food and Drug Administration in 2008 for adjunctive therapy for focal onset seizures in patients 17 years of age and older. The efficacy of this agent in adults has led clinicians to consider lacosamide for children with refractory seizures.The MEDLINE database (1950-June 2012) was searched for abstracts containing lacosamide as the key term. Additional references were obtained from the manufacturer and the bibliographies of the articles reviewed. All available English-language case reports and clinical trials were included in the evaluation.Several case series studies have been published which support the use of lacosamide in children with refractory seizures. In the papers published to date, 30% to 50% of children experienced at least a 50% reduction in seizure frequency, similar to results obtained in clinical trials in adults. Children with focal onset seizures were most likely to benefit from treatment, while results in children with generalized seizures or multiple seizure types were mixed. Adverse effects in children were similar to those seen in adults, with dizziness, headache, and nausea occurring most frequently. Lack of efficacy has been the most common cause of discontinuation.Lacosamide appears to be a useful adjunct therapy in children with refractory seizures. Clinical trials are under way that may provide more definitive information on the efficacy and safety of lacosamide in children and allow clinicians to determine the appropriate place of this antiseizure drug in pediatric epilepsy management.
HubMed – drug
Workplace Substance Use Climate: Prevalence and Distribution in the U.S. Workforce.
Filed under: Drug and Alcohol Rehabilitation
J Subst Use. 2012 Feb 1; 71(1): 72-83
Frone MR
This study explored the prevalence and distribution of employee exposure to three dimensions of workplace substance use climate-availability, descriptive norms, and injunctive norms. Data were collected from a national probability sample of 2148 U.S. wage and salary workers (957 men; 1191 women) using a random digit dialed telephone survey. Aproximately 63.09% of the workforce reported that they could easily bring alcohol into work, use alcohol while working, use alcohol during lunch and other breaks, or obtain alcohol at work. Similarly, 59.05% of the workforce reported that they could easily engage in the same behaviors regarding illicit drugs. During the preceding 12 months, 23.00% of the workforce reported exposure to a coworker who used or was impaired by alcohol during the workday and 12.65% of the workforce reported exposure to a coworker who used or was impaired by an illicit drug during the workday. Approximately, 7.03% of the workforce reported exposure to a coworker who approved of alcohol use or impairment during the workday and 3.55% of the workforce reported exposure to a coworker who approved of using or being impaired by illicit drugs during the workday. The distribution of exposure to a permissive workplace substance use climate differed by gender, age, occupation, and work shift.
HubMed – drug
Translating knowledge from Pakistan’s second generation surveillance system to other global contexts.
Filed under: Drug and Alcohol Rehabilitation
Sex Transm Infect. 2012 Dec 20;
Adrien A, Thompson LH, Archibald CP, Sandstrom PA, Munro M, Emmanuel F, Blanchard JF
BACKGROUND: From 2004 to 2011, a collaborative project was undertaken to enhance the capacity of the Government of Pakistan to implement an effective second-generation surveillance system for HIV/AIDS, known as the HIV/AIDS Surveillance Project (HASP). In four separate rounds, behavioural questionnaires were administered among injection drug users, and female, male and hijra (transgender) sex workers. Dried blood spots were collected for HIV testing. METHODS: Through interviews with project staff in Pakistan and Canada, we have undertaken a critical review of the role of HASP in generating, using and translating knowledge, with an emphasis on capacity building within both the donor and recipient countries. We also documented ongoing and future opportunities for the translation of knowledge produced through HASP. RESULTS: Knowledge translation activities have included educational workshops and consultations held in places as diverse as Colombia and Cairo, and the implementation of HASP methodologies in Asia, the Middle East and sub-Saharan Africa. HASP methodologies have been incorporated in multiple WHO reports. Importantly, the donor country, Canada, has benefited in significant ways from this partnership. Operational and logistical lessons from HASP have, in turn, improved how surveillance is performed in Canada. Through this project, significant capacity was built among the staff of HASP, non-governmental organisations which were engaged as implementation partners, data coordination units which were established in each province, and in the laboratory. As is to be expected, different organisations have different agendas and priorities, requiring negotiation, at times, to ensure the success of collaborative activities. Overall, there has been considerable interest in and opportunities made for learning about the methodologies and approaches employed by HASP. CONCLUSIONS: Generally, the recognition of the strengths of the approaches and methodologies used by HASP has ensured an appetite for opportunities of mutual learning.
HubMed – drug
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Filed under: Drug and Alcohol Rehabilitation
Neuro Oncol. 2012 Dec 20;
Johannessen TC, Prestegarden L, Grudic A, Hegi ME, Tysnes BB, Bjerkvig R
IntroductionGlioblastoma multiforme (GBM; World Health Organization astrocytoma grade IV) is the most frequent and most malignant primary brain tumor in adults. Despite multimodal therapy, all such tumors practically recur during the course of therapy, causing a median survival of only 14.6 months in patients with newly diagnosed GBM. The present study was aimed at examining the expression of the DNA repair protein AlkB homolog 2 (ALKBH2) in human GBM and determining whether it could promote resistance to temozolomide chemotherapy.MethodsALKBH2 expression in GBM cell lines and in human GBM was determined by quantitative real-time PCR (qRT-PCR) and gene expression analysis, respectively. Drug sensitivity was assessed in GBM cells overexpressing ALKBH2 and in cells in which ALKBH2 expression was silenced by small-interfering (si)RNA. ALKBH2 expression following activation of the p53 pathway was examined by western blotting and qRT-PCR.ResultsALKBH2 was abundantly expressed in established GBM cell lines and human GBM, and temozolomide exposure increased cellular ALKBH2 expression levels. Overexpression of ALKBH2 in the U87 and U251 GBM cell lines enhanced resistance to the methylating agents temozolomide and methyl methanesulfonate but not to the nonmethylating agent doxorubicin. Conversely, siRNA-mediated knockdown of ALKBH2 increased sensitivity of GBM cells to temozolomide and methyl methanesulfonate but not to doxorubicin or cisplatin. Nongenotoxic activation of the p53 pathway by the selective murine double minute 2 antagonist nutlin-3 caused a significant decrease in cellular ALKBH2 transcription levels.ConclusionOur findings identify ALKBH2 as a novel mediator of temozolomide resistance in human GBM cells. Furthermore, we place ALKBH2 into a new cellular context by showing its regulation by the p53 pathway.
HubMed – drug
Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases.
Filed under: Drug and Alcohol Rehabilitation
Int J STD AIDS. 2012 Dec; 23(12): 909-10
Rosenblatt A, de Campos Guidi HG
Imiquimod is a topical immune response modifier used to treat anogenital warts. Although considered a safe drug, mild to moderate local and systemic side-effects may occasionally occur. We report three cases of local and systemic adverse effects related to imiquimod, including one case that mimicked meningitis, which promptly resolved with drug cessation.
HubMed – drug
Related Drug And Alcohol Rehabilitation Information…